Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM524GR)

Drug Name

ICP-192 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Bladder cancer	2C94	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Fibroblast growth factor receptor (FGFR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Erdafitinib	DMI782S	Bladder cancer	2C94	Approved	[3]
Futibatinib	DMWM4D0	Intrahepatic cholangiocarcinoma	2C12.10	Approved	[4]
Infigratinib	DMNKBEC	Cholangiocarcinoma	2C12.10	Approved	[5]
HIF-1alpha	DM4OQRD	Lymphoma	2A80-2A86	Phase 4	[6]
ARQ-087	DM02BVQ	Intrahepatic cholangiocarcinoma	2C12.10	Phase 3	[5]
AZD4547	DM3827C	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[5]
Debio 1347	DMZW50O	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
BAY1163877	DMCSGJ2	Bladder cancer	2C94	Phase 2	[8]
PRN1371	DMR7BAO	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
PD173074	DMP0N4U	Nasopharyngeal carcinoma	2B6B	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fibroblast growth factor receptor (FGFR)	TT0LF7H	NOUNIPROTAC	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04492293) An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of InnoCare Pharma.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4	TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Molecular Cancer Therapeutics. 01/2014; 12(11_Supplement):A270-A270.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Tumor angiogenesis as a therapeutic target. Drug Discov Today. 2001 Oct 1;6(19):1005-1024.
7	The fibroblast growth factor receptor genetic status as a potential predictor of the sensitivity to CH5183284/Debio 1347, a novel selective FGFR inhibitor. Mol Cancer Ther. 2014 Nov;13(11):2547-58.
8	Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. Cancer Research. 10/2014; 74(19 Supplement):1739-1739.